Bausch Health Cos (BHC) Projected to Announce Earnings on Wednesday

Bausch Health Cos (NYSE:BHC) will likely be posting its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Bausch Health Cos to announce earnings of $0.96 per share and revenue of $2.5881 billion for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 5:00 PM ET.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. On average, analysts expect Bausch Health Cos to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Cos Stock Performance

Shares of BHC opened at $4.42 on Monday. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The stock has a market capitalization of $1.66 billion, a P/E ratio of -1.37 and a beta of 0.42. The company’s fifty day moving average is $5.00 and its two-hundred day moving average is $5.54. Bausch Health Cos has a 1 year low of $4.33 and a 1 year high of $8.69.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 4th. Royal Bank Of Canada cut their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Finally, Jefferies Financial Group upgraded shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. Five research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $8.00.

Insider Buying and Selling

In other Bausch Health Cos news, Director Frank D. Lee sold 24,456 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total value of $132,796.08. Following the completion of the sale, the director owned 49,339 shares of the company’s stock, valued at approximately $267,910.77. This trade represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in BHC. Oxford Asset Management LLP purchased a new position in shares of Bausch Health Cos in the fourth quarter valued at $422,000. Northwest & Ethical Investments L.P. boosted its position in shares of Bausch Health Cos by 52.3% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 59,984 shares of the company’s stock worth $417,000 after buying an additional 20,592 shares in the last quarter. PDT Partners LLC boosted its position in shares of Bausch Health Cos by 19.6% in the 4th quarter. PDT Partners LLC now owns 50,045 shares of the company’s stock worth $348,000 after buying an additional 8,200 shares in the last quarter. Osaic Holdings Inc. grew its stake in Bausch Health Cos by 19.5% in the 4th quarter. Osaic Holdings Inc. now owns 48,291 shares of the company’s stock valued at $336,000 after acquiring an additional 7,865 shares during the last quarter. Finally, Tidal Investments LLC increased its holdings in Bausch Health Cos by 2.6% during the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock valued at $334,000 after acquiring an additional 1,276 shares in the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.